Caladrius Biosciences: Sicker Than Ever

|
About: Caladrius Biosciences, Inc. (CLBS)
by: Zamir Merali
This article is exclusive for subscribers.
Zamir Merali
Healthcare, value, contrarian
Summary

CLBS attracted bullish interest after it acquired the rights to a CD34+ cell therapy for refractory angina and received RMAT status for this program.

Although a recent meta-analysis of this therapy showed positive results, the only Phase 3 study to-date, the RENEW trial, failed to meet its primary endpoint.

It is likely the FDA will ask CLBS to undertake a very costly and time-consuming Phase 3 trial in order to advance the CLBS14-RfA program.

CLBS does not have the financial resources or expertise to advance this program.

Share Price Up on Good News

Investor interest in Caladrius Biosciences (CLBS) was rekindled after two recent news events. In March, Caladrius acquired the global rights to Shire's (SHPG) CD34+ stem